Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Revenues:
Total revenues	$ (29)	$ 3,032
Operating expenses:
Research and development	108,922	118,645
Selling, general and administrative	23,339	23,944
Restructuring, long-lived assets impairment and related charges, net	0	(10)
Total operating expenses	132,261	142,579
Loss from operations	(132,290)	(139,547)
Other income:
Change in fair value of equity investments	(170)	6,382
Interest income	7,189	12,288
Other expense, net	(254)	(72)
Total other income	6,765	18,598
Loss before provision for income taxes	(125,525)	(120,949)
Provision for income taxes	(170)	(16)
Net loss	$ (125,695)	$ (120,965)
Net loss per share, basic (in USD per share)	$ (0.85)	$ (0.88)
Net loss per share, diluted (in USD per share)	$ (0.85)	$ (0.88)
Weighted-average shares outstanding, basic (in shares)	147,356,811	137,468,900
Weighted-average shares outstanding, diluted (in shares)	147,356,811	137,468,900
License and collaboration revenue
Revenues:
Total revenues	$ (41)	$ (70)
Grant revenue
Revenues:
Total revenues	12	1,238
Other revenue
Revenues:
Total revenues	$ 0	$ 1,864